Mark Ragosa Sells 12,000 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 12,000 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $41.89, for a total value of $502,680.00. Following the completion of the sale, the chief financial officer directly owned 19,086 shares in the company, valued at $799,512.54. This represents a 38.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Mark Ragosa also recently made the following trade(s):

• On Monday, December 8th, Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.49, for a total value of $1,777,473.09.
• On Wednesday, November 12th, Mark Ragosa sold 19,900 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $40.94, for a total value of $814,706.00.
• On Tuesday, October 28th, Mark Ragosa sold 100 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.00, for a total value of $4,100.00.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock opened at $42.67 on Friday. The business’s fifty day moving average price is $41.26 and its 200 day moving average price is $36.36. The firm has a market capitalization of $3.23 billion, a PE ratio of 94.82 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $44.42.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The company had revenue of $180.86 million for the quarter, compared to analysts’ expectations of $166.64 million. During the same quarter in the previous year, the firm posted ($0.18) earnings per share. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 61.2% on a year-over-year basis. Equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 288.6% during the fourth quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock valued at $22,333,000 after acquiring an additional 402,078 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 16.2% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 14,792 shares of the company’s stock worth $610,000 after purchasing an additional 2,063 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 4.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock worth $701,000 after buying an additional 771 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Kiniksa Pharmaceuticals International by 42.3% in the third quarter. JPMorgan Chase & Co. now owns 192,456 shares of the company’s stock valued at $7,473,000 after buying an additional 57,174 shares during the last quarter. Finally, Danske Bank A S purchased a new position in shares of Kiniksa Pharmaceuticals International during the third quarter valued at approximately $1,180,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on KNSA. TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a “buy” rating and a $60.00 price target for the company. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Citigroup upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of “Moderate Buy” and an average price target of $52.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.